

FY2010 (Fiscal Year Ended March 31, 2011) Financial Results Presentation

Eisai Co., Ltd.

-

May 13, 2011

he have

human health care

Safe Harbor Statement



- Materials and information provided during this presentation may contain so-called "forward-looking statements." These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.
- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to productrelated forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; regulatory agency's examination period, obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
- Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.
- The Company disclaims any intention or obligation to update or revise any forwardlooking statements whether as a result of new informatex






FY2009		FY2010			
Results	%	Results	%	YOY	



Sales of Major Products - Aricept - Double-digit growth in Japan



(Billion Yen, %)



Achieved continued growth in Japan and Asia



Sales of Major Products - AcipHex/Pariet -



(Billion yen)







Sales by Segment Progress of regional transformation



FY2009				



Profit by Segment Profit growth in Japan and profitability improvement in U.S.

(Billion Yen, %)

	FY2009			FY2010				
		Results	%	% on Sales	Results	%	% on Sales	YOY
(Billion Yen)	Japan	133.4	49.0	41.4	145.0	54.3	41.4	109
	U.S ^{.*} \$ million	106.6 [1,148]	39.2	29.7	94.4 [1,101]	35.4	31.2	89 [96]
200 -	Europe	6.4	2.3	12.9	4.7	1.8	10.6	74
150 -	Asia	8.1	3.0	26.2	5.9	2.2	18.7	72
100 -	New Markets	(0.3)			(0.7)			
50 -	Reporting Segment Total	254.3	93.4	33.4	249.2	93.4	34.1	98
0 -	Others	17.8	6.6	43.8	17.7	6.6	45.6	99
FY2009 FY2010	R&D expenses & Non-allocated SG&A expenses	(185.7)			(153.8)			
■Japan ■U.S. ■Europe ■Asia ■NM ■Others	Consolidated Operating Profit	86.4		10.8	113.1		14.7	131

Except for "Others", regions above have pharmaceutical businesses

*Segment profit from U.S. pharmaceuticals business in local currency was calculated based on average exchange rate

Secured Financial Position At Initiation of the Plan HAYABUSA Toward global top tier in efficiency indices



	FY2009	FY2010
ROE (%)	9.6	16.4
Equity Spread* (%)	1.6	8.4
DOE (%)	10.1	10.4
EPS (yen)	141.6	236.5
Net DER	0.62	0.49
Operating profit margin (%) (U.S. segment profitability)	10.8 (29.7)	14.7 (31.2)


*Equity Spread = ROE – cost of equity (%) Assuming 8% level of cost of equity



Plan "HAYABUSA" Initiated







"From Discovery to Marketing, we will enhance patient value through further personalization"

Personalized Medicine and Focused Marketing

hhe

Personalized Medicine and Focused Marketing



Personalized Medicine



Focused Marketing

- US: Transform from mass marketing/co-promotion model to independent neuroscience/oncology franchise model
- Europe: Transform from country-based business model to "One Europe" business model
 - Japan: Transform from solo Eisai Japan to the core of East Asia
 - China: Transform from massive field force model to focused approach adaptive to areas and product characteristics



Lean and Efficient Structure in U.S. Transformation from mass model to focused model



Eisai Product Creation Systems 7 Unit HQs

Oncology PCU^{*1}, Neuroscience PCU, Morphotek PCU, Global Regulatory CFU^{*2}, Scientific & Operation Clinical Support CFU Pharmaceutical Science & Technology CFU Biomarker & Personalized Medicine CFU

Global Launch Team

Established strategy HQ that aligns product creation, manufacturing, and commercial in the U.S., the first country to launch products Halaven perampanel farletuzumab Aricept 23mg

RTP

(Research Triangle Park Plant) Transition from two shifts to one Formulation and execution of global logistics strategy Parenteral formulations (Halaven) Global backup site

Commercial

Focus on on<mark>cology and n</mark>euroscience Patient access and efficient marketing New lean sales force structure with approx. 560^{*3} MRs Primary Care (approx. 440^{*3}) and Oncology (approx. 120^{*3})


Patient Contribution

*1 PCU: Product Creation Unit
*2 CFU: Core Function Unit
*3: Number of MRs as of April 1, 2011





human health





Japan Pharmaceutical Business New addition of skyrocketing 'rising stars' to prosperous 'big2' in-line drivers



Aricept and Pariet to continue double-digit growth

Aricept: 105.5 billion yen (+13%); the 3rd best-selling product among all pharmaceutical products in Japan in FY2010^{*1}
 Full-stage penetration rate: 60.5%^{*2} (+3.3%), sales growth of 10mg formulation (+31%)



*1© IMS Japan JPM April 2010 – March 2011 *2 Internal estimates





Disease solution






Acceleration of Product Creation



Further Contribution in Oncology through Approval of Halaven in Japan




World's first simultaneous submissions in Japan, U.S., and E.U. to minimize drug lag



Worldwide: approx. 1 million women worldwide are newly diagnosed with breast cancer each year; approx. 40% of which will go on to develop locally advanced or metastatic disease


U.S.: approx. 200,000 women are newly diagnosed with advanced breast cancer each year Europe: breast cancer strikes 110 out of every 100,000 people



19








Eisai Oncology Presentations


2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) (19 Abstracts)



hhe human beath same

Contribution to Unmet Medical Needs with Significant Market Potential





FDA provided guidance at the End-of-

- Target indications: idiopathic thrombocytopenic purpura (ITP), thrombocytopenia associated with liver diseases (TLD), chemotherapyinduced thrombocytopenia (CIT)
 - Novel compound (oral formulation) of thrombopoietin receptor full agonist to stimulate increase of platelets
- ITP: preparing for phase III; TLD: phase II study ongoing; CIT: preparing for phase II study
- Target submission: ITP in FY2013 (U.S. and Europe)



Continuous Contributions to AD Patients

Aricept 23mg a treatment for moderate to severe AD patients with few treatment options



- Sales of Aricept franchise in FY2010 \$1,790M (-15%)
 - Aricept franchise maintained approx. 70%^{*} prescription share in donepezil market after LO
 - Seek 20's % level of prescription share in FY2011

Efforts to increase sales of Aricept 23mg

- 6 poster presentations on Aricept 23mg (abstracts) at the 63rd American Academy of Neurology Meeting à Favorable data was presented for cognition (language, etc.), safety and tolerability of Aricept 23mg
- Increased the number of clinical nurse educators for long-term care facilities

Initiated ads with 30-day free trial coupon in magazines (People,

Time, etc.) in late February




Creation of disease modifier for AD



Novel humanized monoclonal antibody that removes neurotoxic beta-amyloid protofibrils, which is considered a








Creation of Shareholder Value



Shareholder Value Enhancement by Improving Capital Efficiency (Target for FY2011)





* Equity Spread = ROE – cost of equity (%) Assuming 8% level of cost of equity









Reference Data





(Billion yen, %)

	FY2	2009	FY2010		
	Results	%	Results	%	ΥΟΥ
Sales	322.2	100.0	350.4	100.0	109
Prescription	288.5	89.5	311.1	88.8	108



(MM US\$, %)

		FY20	FY2009		FY2010	
		Results	%	Results	%	YOY
Sales	5	3,865	100.0	3,535	100.0	91
Aric	ept	2,097	54.2	1,790 ^{*1}	50.6	85
Acip	oHex	872	22.6	765	21.6	88
	Halaven					



Performance of Europe Pharmaceuticals Business

(Billion yen, %)

	FY20	009	FY2010			
	Results	%	Results	%	ΥΟΥ	
Sales	49.5	100.0	44.4	100.0	90 [103]	
Aricept	27.9	56.3	24.4	55.0	87 [100]	
Pariet	8.2	16.6	6.4	14.4	78 [88]	
Zonegran	4.4	8.9	4.3	9.8	98 [112]	
Segment Profit	6.4	12.9	4.7	10.6	74	

Sales forecast for FY2011 is 50 billion yen



[]Based on local currency





(Billion yen, %)

	FY2009		FY2010		
	Results	%	Results	%	YOY
Sales	31.1	100.0	31.3	100.0	101 [105]
Methycobal	8.4	27.0	7.1	22.6	84 [89]
Aricept	6.6	21.3	6.9	22.1	105 [108]
Pariet	4.8	15.5	4.5	14.3	93 [96]
HUMIRA	2.3	7.4	3.3	10.5	144 [148]
Stronger Neo-Minophagen C/ Glycyron Tablets	3.0	9.6	3.0	9.6	101 [107]
Segment Profit	8.1	26.2	5.9	18.7	72

[]based on local currency

	FY2009		FY2010			
	Results	%	Results	%	ΥΟΥ	
Sales	1,156	100.0	1,106	100.0	96	
Methycobal	540	46. 7	M5()] TJETBT484	42.9	88	-
Stronger Neo-Minophage0.1138U3(iB	T1 0 0 1 41 0 T6	G92.59i] TJ0 ⁻	1 492.53 99T1 0 6I	(inop538 I	60.25 w0.498 G21 0) 6II(
						-
						_
35					hh	e

2 118715 w0.49742 19 BTETB[(15()] TJETBT18)] TJ98.78 143.3 Tm[(1.)-3(1 0 0 1 34.584 261.46 Tm[()4()-3()] TJETBT1()-3()] TJETBT1()-3()]



	FY2010	FY2011	FY2012	FY2013	FY2014 and thereafter
Neurology	Aricept patch* Alzheimer's disease (AD)	perampanel adjunctive therapy for partial seizures	Aricept Lewy body dementia		E2212 AD E2609 AD Perampanel monotherapy partial onset seizures BAN/2401 AS-3201
Oncology			eribulin refractory breast cancer with fewer prior treatments lenvatinib melanoma		MORAb-009 mesotheliomaMORAb-028 melanomaONTAK peripheral T-cell lymphomaMORAb-004 solid cancerE7050 solid cancer
Critical care		HUMIRA* ulcerative colitis HUMIRA* joint destruction		E5501 Idiopathic thrombocytopenic purpura	MORAb-022 E5501 Thrombocytopenia associated With liver disease - short E5501 Thrombocytopenia associated Thrombocytopenia associated With liver disease - long
GI, Urology, etc.	Pariet GERD twice daily	Uritos overactive bladder			

